Arrowstreet Capital
STRO icon

Arrowstreet Capital’s Sutro Biopharma STRO Stock Holding History

Arrowstreet Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,767
Closed -$2.55M – 1972
2024
Q3 		$2.55M Buy
73,767
+72,401
+5,300% +$2.84M ﹤0.01% 1169
2024
Q2 		$40K Buy
+1,366
New +$54K ﹤0.01% 1479
2021
Q2 		– Sell
-2,730
Closed -$621K – 2201
2021
Q1 		$621K Buy
+2,730
New +$648K ﹤0.01% 1945
2020
Q3 		– Sell
-1,244
Closed -$97K – 2510
2020
Q2 		$97K Buy
+1,244
New +$119K ﹤0.01% 2225

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Arrowstreet Capital's STRO Position: Q4 2024 in Review

Arrowstreet Capital sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 73,767 shares — an estimated $2.55M sold.

Arrowstreet Capital first reported a position in STRO in Q2 2020 and held it in 4 quarters. The position peaked at $2.55M in Q3 2024. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Arrowstreet Capital reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 73,767 Sutro Biopharma shares in Q4 2024, an estimated $2.55M.
  • Arrowstreet Capital first reported a position in Sutro Biopharma in Q2 2020 and held it in 4 quarters.
  • Arrowstreet Capital's Sutro Biopharma position peaked at $2.55M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Arrowstreet Capital's 13F filing for Q4 2024, filed 12 Feb 2025.